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Abstract
Background and Aims: Crohn’s disease [CD] is characterised by chronic intestinal inflammation and 
dysbiosis in the gut. Riboflavin [vitamin B2] has anti-inflammatory, antioxidant and microbiome-
modulatory properties. Here, we analysed the effect of riboflavin on oxidative stress, markers of 
inflammation, clinical symptoms, and faecal microbiome in patients with CD.
Methods: In this prospective clinical intervention study, patients received 100  mg riboflavin 
[DSM, Nutritional Products Ltd] daily for 3 weeks. Clinical disease activity [Harvey-Bradshaw 
Index: HBI], serum biomarkers of inflammation and redox status [plasma free thiols], and faecal 
microbiome taxonomical composition and functionality [fluorescent in situ hybridisation: FISH; and 
metagenomic shotgun sequencing: MGS], were analysed before and after riboflavin intervention.
Results: In total, 70 patients with CD with varying disease activity were included. Riboflavin 
supplementation significantly decreased serum levels of inflammatory markers. In patients with 
low faecal calprotectin [FC] levels, IL-2 decreased, and in patients with high FC levels, C-reactive 
protein [CRP] was reduced and free thiols significantly increased after supplementation. Moreover, 
HBI was significantly decreased by riboflavin supplementation. Riboflavin supplementation led to 
decreased Enterobacteriaceae in patients with low FC levels as determined by FISH; however, MGS 
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Conclusions: Three weeks of riboflavin supplementation resulted in a reduction in systemic 
oxidative stress, mixed anti-inflammatory effects, and a reduction in clinical symptoms [HBI]. FISH 
analysis showed decreased Enterobacteriaceae in patients with CD with low FC levels, though this 
was not observed in MGS analysis. Our data demonstrate that riboflavin supplementation has a 
number of anti-inflammatory and anti-oxidant effects in CD.
Key Words: Crohn’s disease; riboflavin [vitamin B2]; clinical intervention study
1. Introduction
Crohn’s disease [CD] is a chronic inflammatory disease of the gastro-
intestinal tract and is characterised by a relapsing-remitting disease 
course.1 Its incidence is increasing globally, in particular in the recent 
decades and especially in regions adopting a Western lifestyle.2 CD is 
accompanied by a high patient burden and impaired quality of life.3 
A complex interaction between inherited and environmental factors, 
the gut microbiome, and the host immune response are causative in 
the pathogenesis of CD.4–7
Thus, CD has a multifactorial aetiology, and is characterised by 
relapsing intestinal inflammatory events. Reducing these inflamma-
tory events is an important therapeutic target to improve the quality 
of life of patients with CD. Such an approach of reducing inflamma-
tory intestinal events may be accomplished by supplementation of 
the diet with anti-inflammatory food components. Riboflavin is such 
a component with anti-inflammatory potential.
Riboflavin is a water-soluble vitamin that plays a key role 
in several metabolic pathways, including human energy metab-
olism. Previous studies have demonstrated that riboflavin exerts 
anti-inflammatory and antioxidant effects in animal models of 
CD.8–11 For instance, administration of either pure riboflavin or 
riboflavin-producing bacteria ameliorates chemically-induced colitis 
in mice.8 Similarly, other experimental animal studies have demon-
strated anti-inflammatory effects of riboflavin, such as a decrease 
in the production of pro-inflammatory cytokines, tumour necrosis 
factor-α [TNF-α], and interleukin-6 [IL-6], and a potentiating effect 
on the anti-inflammatory action of dexamethasone.9
It is currently unknown whether riboflavin alleviates inflamma-
tion and oxidative stress directly, by modulating the patient’s im-
mune system, or indirectly, by altering the composition of the gut 
microbiome. The latter seems of particular interest, since the gut 
microbiome of patients with CD is characterised by a reduced micro-
biota diversity compared with healthy individuals.12 One of the most 
prominent effects on species level is a reduction in the abundance of 
the commensal bacterium Faecalibacterium prausnitzii.13–19 This bac-
terial species has anti-inflammatory properties and is a potent pro-
ducer of short-chain fatty acids [SCFAs], particularly butyrate.15,17 
In a pilot study in healthy individuals, it was demonstrated that a 
2-week supplementation period of riboflavin resulted in an increase 
in the faecal abundance of F. prausnitzii.11
We designed a prospective clinical intervention study in patients 
with CD to further clarify the effect of riboflavin on multiple disease 
parameters. Because disease activity may affect the success rate of 
riboflavin interventions, we evaluated the effect of riboflavin sup-
plementation in patients with either low or high faecal calprotectin 
levels separately. We hypothesised that riboflavin supplementation 
in patients with CD will show anti-inflammatory and antioxi-
dant effects, resulting in a reduction of faecal calprotectin levels, 
C-reactive protein [CRP], and pro-inflammatory cytokines, and an 
improvement of systemic redox status, disease-specific symptoms, 
and quality of life [QoL], and that such effects may be mediated by 
changes in the faecal microbiome composition. Therefore, we ana-
lysed the effect of riboflavin on clinical disease scores, circulating 
inflammatory biomarkers, and systemic redox status, as well as on 
the faecal microbiota composition and functionality.
2. Materials and Methods
2.1. Study population
Patients aged 19–67  years were included from March 2016 until 
April 2017 from the IBD outpatient clinic of the University Medical 
Center Groningen [UMCG]. All patients had an established diag-
nosis of CD existing for at least 1 year, based on clinical, endoscopic, 
and histopathological criteria.
Patients were included and divided into two groups according 
to inflammatory disease activity, as determined by the faecal 
calprotectin [FC] level. The first group consisted of patients with low 
FC levels [defined as a faecal calprotectin level <200 µg/g] and the 
second group consisted of patients with high FC levels [defined by 
faecal calprotectin level >200 µg/g].
Exclusion criteria were as follows: swallowing disorders; preg-
nancy and lactation; use of antibiotics, probiotics, or specific 
prebiotic supplements in the 3 weeks preceding the riboflavin inter-
vention; use of methotrexate drugs; colonoscopy or colon cleansing 
in the past 3 months; and severe CD activity (defined as a Harvey-
Bradshaw Index [HBI] >12). In addition, patients using a vitamin B2 
supplement, or multivitamin complexes containing B vitamins [i.e., 
vitamin B complexes] in the 3 weeks preceding the riboflavin inter-
vention were excluded from the study. Concomitant medication use 
for CD was allowed in all study groups. However, patients who re-
ported changes in medication use during the study period as well as 
within 3 months preceding potential inclusion, were excluded from 
the study. No adverse events occurred in this study.
2.2. Ethical considerations
This prospective clinical intervention study has been approved by 
the Institutional Review Board [IRB] [in Dutch: ‘Medisch Ethische 
Toetsingscommissie’, METc] of the UMCG [IRB no. 2014/291] and 
registered on ClinicalTrials.gov [NCT02538354]. All patients pro-
vided written informed consent in accordance with the Declaration 
of Helsinki [2013].
2.3. Data collection and study design
At the time of inclusion, standard demographic characteristics, 
including age, sex, body mass index [BMI], smoking behaviour, and 
alcohol consumption, were recorded as well as CD-specific disease 
parameters [e.g., disease course, disease localisation, current CD 
maintenance therapy]. For each patient, the Montreal disease clas-
sification was used to determine the disease phenotype [including 
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age at diagnosis, localisation of the disease, and disease behaviour]. 
Moreover, CD-related surgical history was recorded. In addition, as 
a clinical measure of disease activity, the HBI was documented. All 
patients with CD were encouraged to maintain their normal dietary 
habits during the study period. Patients completed an extensive 
Food Frequency Questionnaire [FFQ] to obtain information on their 
habitual dietary intake [see Supplementary Methods, available as 
Supplementary data at ECCO-JCC online].
Patients were requested to collect faecal samples at home and 
store the samples in their home freezers, immediately after pro-
duction. Two baseline samples [T0] were collected before the ribo-
flavin intervention, to correct for day-to-day variation. Additional 
faecal samples were collected after 3 weeks of supplementation 
with riboflavin [T3]. Frozen faecal samples were transported to the 
UMCG on dry ice and stored at -80°C. Furthermore, the HBI and 
the Inflammatory Bowel Disease Questionnaire [IBD-Q] were com-
pleted and blood samples were collected and stored at -80 °C before 
and after riboflavin supplementation.
The period of riboflavin supplementation was based on the pre-
viously mentioned pilot study in healthy individuals, in which we 
observed a significant increase in F. prausnitzii abundance already 
after 2 weeks.11 However, in the present study consisting of patients 
with CD, we investigated the effect of riboflavin on many different 
outcomes, including outcomes of disease activity and quality of life. 
Due to clinical logistics, the study period was set to be a period of 3 
weeks of riboflavin supplementation.
2.4. Riboflavin capsules
Patients received daily riboflavin supplementation of the normal 
diet for a period of 3 weeks. The riboflavin supplement consisted of 
100 mg of riboflavin [Riboflavin Universal, CAS no. 83-88-5] per cap-
sule [DSM Nutritional Products Ltd, Basel, Switzerland]. Additional 
information on the capsule is included in the Supplementary 
Methods.
2.5. Laboratory parameters, serum cytokines and 
plasma free thiols [R-SH, sulphhydryl groups], and 
faecal calprotectin
Routine blood analyses were performed before and after the inter-
vention, including CRP, erythrocyte sedimentation rate [ESR], plate-
lets, white blood cell count [WBC], haemoglobin, liver function tests, 
and creatinine. In addition, serum riboflavin level [flavine adenine 
dinucleotide] was measured before and after supplementation.
To determine a potential effect on systemic inflammation and 
redox status, serum cytokines and plasma free thiols were quanti-
fied, respectively. Serum levels of multiple cytokines, chemokines, 
and markers for angiogenesis and vascular injury were meas-
ured before and after the riboflavin intervention period, using the 
electrochemiluminescence [ECL] multiplex assay (Meso Scale 
Discovery [MSD ®]), as previously described.20 The MSD V-plex Pro-
inflammatory panel 1 [IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12p70, IL-13, and TNF-α], Cytokine panel 1 [GM-CSF, IL-5, IL-7, 
IL-12/23p40, IL-15, IL-16, IL-17A, and TNF-β], Chemokine panel 1 
[Eotaxin-1, MIP-1β, Eotaxin-3, TARC, IP-10, MIP-1α, MCP-1, and 
MDC], Angiogenesis panel 1 [VEGF, VEGF-C, VEGF-D, Tie-2, Flt-
1, PIGF, bFGF] and Vascular injury panel 1 [SAA, CRP, VCAM-1, 
and ICAM-1] were analysed to detect a total of 37 inflammatory 
molecules. Plasma free thiol groups were measured as previously 
described, with minor modifications [detailed in Supplementary 
Methods].21,22 Final concentrations were corrected for plasma 
albumin levels, since albumin is the most abundant human plasma 
protein and is the predominant source of thiols.23
Faecal calprotectin levels were quantified by enzyme-linked 
immunosorbent assay [ELISA] [Bühlmann Laboratories AG, 
Switzerland] as a routine measurement in the UMCG.
2.6. Patient-reported outcome measures: Harvey 
Bradshaw Index [HBI] and Inflammatory Bowel 
Disease Questionnaire [IBD-Q]
To assess the effect of riboflavin on patient-reported outcome meas-
ures, the Harvey-Bradshaw Index [HBI] and the Inflammatory Bowel 
Disease Questionnaire [IBD-Q] were used as measures of clinical dis-
ease activity and quality of life, respectively. The HBI and IBD-Q 
were determined before and after the intervention with riboflavin.
The HBI consists of a short questionnaire used to give a clinical 
reflection of disease activity, based on a number of clinical param-
eters: general well-being, abdominal pain, number of liquid stools 
per day, abdominal mass, and a number of CD-associated extra-
intestinal complications.24 Generally, in clinical practice, an HBI 
score <5 is defined as clinical remission.
The IBD-Q distinguishes physical domains [i.e., bowel symptoms 
and systemic symptoms] and psychosocial domains [i.e., emotional 
function and social function] by means of 32 disease-related ques-
tions. Response scores theoretically range from 32 to 224 points, 
where higher values correspond to an improved health status.
2.7. Microbiome analyses
2.7.1. Fluorescence in situ hybridisation
The faecal microbiota were measured by fluorescence in situ hybrid-
isation [FISH]. Using this method, the abundance of the following 
bacteria were quantified in absolute counts: total bacteria [EUB338, 
Rhodamine], F.  prausnitzii [Fprau645, FITC], Enterobacteriaceae 
[Ec1531, CY3], and the Clostridium coccoides-Eubacterium rectale 
group [mostly Lachnospiraceae] [Erec482, FITC]. The FISH meth-
odology is described in the Supplementary Methods.25
2.7.2. Whole genome metagenomic shotgun sequencing
The taxonomical and functional [i.e., metabolic pathway] compos-
ition of the faecal microbiome were also characterised in higher 
resolution, by means of whole genome metagenomic shotgun 
sequencing [MGS]. From the frozen faecal samples, the microbial 
DNA was extracted using the Qiagen Allprep DNA/RNA Mini Kit 
[cat #380204]. The metagenomic shotgun sequencing of the micro-
bial DNA was executed at the Broad Institute of Harvard University 
and the Massachusetts Institute of Technology [MIT] in Cambridge, 
MA, USA, using the HiSeq platform. The Nextera XT Library prep-
aration kit was used for genomic library preparation. To remove 
adapters and trim the ends of the metagenomic reads, Trimmomatic 
[v.0.32] was used.12,26
The cleaned metagenomic reads were processed using the pre-
viously published bioinformatics pipeline.12 First, the software 
tool MetaPhlAn2 was used to profile the taxonomic compositions 
expressed in relative abundances of the microbiome samples.27 
Second, the composition of functional pathways expressed in rela-
tive abundances was determined using the software HUMAnN2 
[v.0.4.0] [http://huttenhower.sph.harvard.edu/humann2] and the 
multi-organism database MetaCyc (MetaCyc. MetaCyc Metabolic 
Pathway Database; available at: https://metacyc.org]) [accessed 
January 1, 2017]. This resulted in the identification of 295 different 
taxa and 341 microbial pathways in the faecal microbiome samples.
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The taxonomic diversity [α-diversity] within the faecal 
microbiome samples was estimated using the Shannon diversity 
index by means of the vegan package in R [version 2.4.-1].28 The 
interindividual diversity [β-diversity] was calculated via Bray-Curtis 
distances between samples, and were represented in principal coord-
inate analyses [PCoAs]. To test the proportion of explained variance 
in the inter-individual distances [i.e. Bray-Curtis distances] per clin-
ical characteristic, the ADONIS function in the vegan package was 
used. Significance was calculated using 1000 permutations and a 
cut-off at test false-discovery rate [FDR] <0.1. Lastly, specific taxa 
and functional pathways were compared between before and after 
the intervention, by means of a paired Wilcoxon signed-rank test, 
with p-values adjusted for multiple testing using the Benjamini-
Hochberg method for FDR. An FDR <0.1 was considered as stat-
istically significant. For a detailed description of the statistics and R 
code, see Supplementary Methods.
2.8. Statistics
For detailed description of statistical analyses, see Supplementary 
Methods.
3. Results
3.1. Baseline characteristics of the study population
Initially, 79 patients with CD were enrolled in the study, of whom 
nine were excluded because of the following reasons: patients who 
developed an infection during the study and were treated with anti-
biotics [n = 2]; patients who developed an unrelated medical con-
dition before the riboflavin supplementation [n = 2]; and patients 
who withdrew for personal reasons during the study period [n = 5]. 
For the faecal metagenomic sequencing analyses, patients with CD 
were excluded if the quality of the gut metagenomes was deemed 
insufficient [read depth below 10 million reads or contamination 
with human reads] [n = 6]. Eventually, the total study population 
analysed in this study consisted of 70 patients with CD, among 
whom 40 patients had low FC levels [<200 µg/g] and 30 patients 
had elevated FC levels [>200 µg/g]. The baseline cohort demographic 
and clinical characteristics are presented in Table 1. Adherence to 
the riboflavin supplement was confirmed by a significant increase 
in serum levels of riboflavin for the complete CD study cohort 
[p <0.001]; [Supplementary Table S1, available as Supplementary 
data at ECCO-JCC online]. In addition, energy intake [kcal] and 
macronutrients were quantified at baseline for all patients with CD 
using the FFQ [Supplementary Table S2, available as Supplementary 
data at ECCO-JCC online]. There was no significant difference in 
energy intake or macronutrient intake between patients with low 
and high FC. As expected, patients with CD with high FC levels had 
consistently higher CRP levels and an elevated ESR [p <0.001 and 
p <0.01, respectively]. No adverse events were observed in this study.
3.2. Riboflavin supplementation improves systemic 
redox status
The effect of riboflavin on systemic redox status was assessed by 
determining the concentrations of albumin-adjusted free thiols in 
plasma [Supplementary Table S3 available as Supplementary data at 
ECCO-J CC online]. In the total CD study cohort, the concentration 
of free thiols significantly increased after 3 weeks of supplementa-
tion [Figure  1]. The largest effect on free thiols was observed for 
patients with CD with elevated FC levels: mean concentrations were 
significantly elevated after the intervention period [p = 0.033]. For 
patients with low FC levels, no significant increase was observed. 
In line, we did not observe major differential effects of riboflavin 
on albumin-adjusted plasma free thiols for several important disease 
phenotypes, such as ileocaecal resection status and primary disease 
localisation [Supplementary Figure S1 available as Supplementary 
data at ECCO-JCC online].
3.3. Riboflavin decreases serum levels of cytokines 
and inflammatory parameters
To assess the effects of riboflavin supplementation on inflamma-
tory status in CD, an array of selected serum cytokines was meas-
ured before [T0] and after 3 weeks of riboflavin supplementation 
[T3] (see Table  2 and Supplementary Tables S4–S6 [available as 
Supplementary data at ECCO-JCC online] for the complete list of all 
analysed serum cytokines for the CD cohort, the low FC [<200 µg/g] 
subgroup and the high FC [>200 µg/g] subgroup). Distributions of 
a selection of analysed serum cytokines are illustrated in Figure 2 
[CRP, and IL-2].
In the total study population, concentrations of interleukin-2 
[IL-2] significantly decreased after 3 weeks of riboflavin supplemen-
tation [p = 0.004]. In the subgroup analysis, patients with CD with 
low FC levels showed a significant decrease in serum IL-2 concen-
trations [p = 0.010], whereas patients with high FC levels showed 
no difference after supplementation [p = 0.124]. However in these 
patients, serum CRP concentrations, as measured by the ECL assay, 
significantly decreased after the riboflavin supplementation period 
[p = 0.010]. TNF-α also decreased in the group of patients with high 
FC levels [p = 0.044]; however, this significant finding was lost after 
correction for multiple testing. No significant differences in serum 
cytokine concentrations were observed after 3-week riboflavin 
supplementation for IL-1β, IL-4, IL-6, and IL-10 [Table 2]. Of the 
routinely measured laboratory parameters, CRP, ESR, and platelet 
counts significantly decreased after 3 weeks of riboflavin supple-
mentation in the total CD study population [p = 0.017; p = 0.034; 
p = 0.011, respectively] [Supplementary Table S1]. Platelet count 
was also reduced in the subgroup of patients with CD with low 
FC levels [p = 0.021]. Levels of CRP, derived from the standard la-
boratory measurements, were significantly decreased by riboflavin 
supplementation in patients with high FC levels [p = 0.009], but 
not for the patients with low FC levels at baseline. No significant 
reduction in FC levels was observed after the period of riboflavin 
supplementation.
3.4. Riboflavin supplementation reduces CD 
symptoms [HBI]
Clinical disease activity was measured at baseline [T0] and after the 
3-week period [T3] of riboflavin supplementation [Table  3]. The 
HBI slightly improved after supplementation [T3] in the total IBD 
study cohort, which was a statistically significant decrease [p <0.001]. 
Also, in subgroups, patients with either low FC or high FC levels 
showed a significant improvement of the HBI [p <0.001; p = 0.007, 
respectively].
3.5. Riboflavin improves IBD-related Quality of Life 
[QoL] 
Subjective QoL was quantified by the validated IBD-Q question-
naire [Table 4]. In the total study population, we observed a sig-
nificant increase in response scores for both physical domains, i.e., 
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bowel symptoms and systemic symptoms [p <0.01 and p <0.001, 
respectively]. A  similar result was found for patients with CD 
with low FC levels [bowel symptoms p <0.01, systemic symptoms 
p <0.001]. However, no significant differences in self-reported 
IBD-related QoL were observed in patients with CD with high 
FC levels.
3.6. Riboflavin supplementation decreased 
Enterobacteriaceae in patients with CD with low FC 
levels as determined by FISH, though MGS analysis 
did not show effects on the faecal microbiome 
composition or metabolic profile.
3.6.1. Fluorescence in situ hybridisation shows a decrease in 
Enterobacteriaceae
Riboflavin supplementation was associated with a significant 
decrease in the relative abundance of potentially pathogenic 
Enterobacteriaceae [including Escherichia coli] in the patients 
with low FC levels, but it was not found to affect the number of 
F. prausnitzii in the total study cohort nor in any of the subgroups 
[Supplementary Tables S7 and S8 and Supplementary Figure S2, 
available as Supplementary data at ECCO-JCC online].
3.6.2. Riboflavin supplementation did not affect faecal short-
chain fatty acids [SCFAs] concentrations
Moreover, riboflavin supplementation did not change faecal concen-
trations of the short-chain fatty acids [SCFAs] acetate, propionate, 
and butyrate [Supplementary Table S9 and Supplementary Figure S3, 
available as Supplementary data at ECCO-JCC online]. However, 
we did detect a positive correlation between the relative abundance 
of F. prausnitzii and the concentrations of butyrate in the baseline 
faecal samples. Relative abundances of Enterobacteriaceae showed 
a negative correlation with the concentration of butyrate at base-
line [Supplementary Table S10, available as Supplementary data at 
ECCO-JCC online].
Table 1. Baseline demographic and clinical characteristics of the study population [n = 70] consisting of patients with CD with low and high 
faecal calprotectin [FC] levels.
Characteristics Total FC <200 µg/g FC >200 µg/g p-value
 n = 70 n = 40 n = 30  
Age [years] 41.9 [12.7] 44.2 [11.6] 38.8 [13.6] 0.080
Female gender 48 [68.6] 29 [72.5] 19 [63.3] 0.446
BMI [kg/m2] 25.1 [5.0] 25.1 [5.3] 25.0 [4.7] 0.923
Active smoking 13 [18.6] 7 [17.5] 6 [20.0] 1.000
Ileocaecal resection 28 [40.0] 19 [47.5] 9 [30.0] 0.217
Montreal, location    0.037*
L1 [ileal disease] 28 [40.0] 21 [52.5] 7 [23.3]  
L2 [colonic disease] 11 [15.7] 6 [15.0] 5 [16.7]  
L3 [ileocolonic disease] 31 [44.3] 13 [32.5] 18 [60.0]  
Montreal, behaviour    0.826
B1 [non-stricturing, non-penetrating] 34 [48.6] 19 [47.5] 15 [50.0]  
B2 [stricturing] 27 [38.6] 15 [37.5] 12 [40.0]  
B3 [penetrating] 9 [12.9] 6 [15.0] 3 [10.0]  
HBI    0.857
Remission [<5] 49 [70.0] 29 [72.5] 20 [66.7]  
Mild disease [5–7] 13 [18.6] 7 [17.5] 6 [20.0]  
Moderate disease [8–12] 8 [11.4] 4 [10.0] 4 [13.3]  
IBD medication    0.484
None 20 [28.6] 14 [35.0] 6 [20.0]  
5-ASA 9 [12.9] 6 [15.0] 3 [10.0]  
Thiopurines 16 [22.9] 7 [17.5] 9 [30.0]  
Anti-TNF 18 [25.7] 10 [25.0] 8 [26.7]  
Thiopurine + Anti-TNF 7 [10.0] 3 [7.5] 4 [13.3]  
Laboratory parameters     
Haemoglobin [mmol/l] 8.6 [0.9] 8.6 [1.0] 8.5 [0.9] 0.792
CRP [mg/l]* 1.8 [0.6;4.6] 0.9 [0.5;2.7] 3.6 [1.5;8.0] 0.001*
ESR [mm/h]* 13.0 [5.0;23.5] 11.0 [4.0;18.5] 20.0 [8.5;30.5] 0.005*
WBC [x 109/l] 7.1 [2.1] 6.7 [2.1] 7.6 [2.0] 0.090
Platelets [x 109/l] 287 [76] 273 [80] 307 [67] 0.060
AST [U/l] 23.5 [7.3] 23.9 [6.1] 23.0 [8.8] 0.628
ALT [U/l]* 18.5 [14.0;26.0] 18.5 [14.3;27.3] 18.5 [13.5;26.0] 0.717
Creatinine [µmol/l] 72.7 [13.2] 73.2 [14.0] 72.0 [12.2] 0.717
Riboflavin [nmol/l] 324 [60] 308 [56] 342 [62] 0.121
Data are presented as numbers (proportions, n [%]), mean [SD] or *median (interquartile range [IQR]) in case of skewed variables. Differences between groups 
were tested with independent samples t tests or MannWhitney U tests for non-normally distributed continuous variables, and chi square test or Fisher’s exact test 
for nominal variables, as appropriate. Two-sided p-values <0.05 were considered as statistically significant. Significances are indicated in bold.
FC, faecal calprotectin; IBD, inflammatory bowel disease; BMI, body mass index; HBI, Harvey-Bradshaw Index; 5-ASA, 5-aminosalicylic acid; TNF, tumour 
necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; AST, aspartate transaminase; ALT, alanine trans-
aminase; SD, standard deviation.
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Figure 1. [A–C]. Riboflavin supplementation for 3 weeks [T0-T3] leads to an improved systemic redox status as reflected by increased plasma free thiol levels 
[adjusted for albumin, µM/g]. [A] Albumin-adjusted plasma free thiols significantly increase after 3 weeks of riboflavin supplementation, Total CD cohort [p <0.05]. 
[B] There is no significant change in albumin-adjusted plasma free thiol levels in patients with CD with low FC levels [<200 µg/g]. [C] Patients with CD with high 
FC levels [>200 µg/g] demonstrate significantly increased albumin-adjusted plasma free thiol levels [p <0.05]. *p <0.05 [two-sided]. CD, Crohn’s disease; FC, 
faecal calprotectin.
Table 2. Effects of 3 weeks’ riboflavin supplementation on biomarkers of inflammation: CRP, an array of pro-inflammatory cytokines and 
FC levels.
Total study population T0 T3 p-value
CRP 3.71 x 107 [9.30 x 106; 1.35 x 108] 3.20 x 107 [9.69 x 106 ; 9.32 x 107] 0.308
TNF-α 3.35 [2.61; 4.14] 3.03 [2.54; 3.53] 0.119
IL-2 0.18 [0.12; 0.24] 0.12 [0.07; 0.17] 0.004*
IL-1β 0.05 [0.04; 0.13] 0.04 [0.02; 0.11] 0.189
IL-4 0.04 [0.02; 0.06] 0.03 [0.01; 0.05] 0.197
IL-6 1.00 [0.57; 1.64] 0.83 [0.52; 1.50] 0.336
IL-10 0.32 [0.22; 0.52] 0.38 [0.19; 0.45] 0.834
FC 155 [43; 479] 145 [46; 465] 0.337
FC <200 µg/g T0 T3 p-value
CRP 1.36 x 107 [5.45 x 106; 5.62 x 107] 1.01 x 107 [4.52 x 106; 7.50 x 107] 0.715
TNF-α 3.05 [2.46; 3.63] 2.84 [2.52; 3.31] 0.848
IL-2 0.18 [0.12; 0.23] 0.10 [0.07; 0.17] 0.010*
IL-1β 0.05 [0.04; 0.08] 0.03 [0.01; 0.04] 0.056
IL-4 0.04 [0.02; 0.07] 0.03 [0.01; 0.05] 0.334
IL-6 0.77 [0.39; 1.06] 0.67 [0.36; 1.13] 0.520
IL-10 0.29 [0.19; 0.41] 0.28 [0.17; 0.45] 0.931
FC 55 [40; 128] 61 [40; 110] 0.846
FC >200 µg/g T0 T3 p-value
CRP 6.61x106 [3.66 x 106; 2.15 x 107] 5.47 x 106 [2.31 x 106; 1.55 x 107] 0.010*
TNF-α 3.50 [2.83; 4.60] 3.31 [2.63; 4.00] 0.044
IL-2 0.18 [0.11; 0.26] 0.12 [0.09; 0.18] 0.124
IL-1β 0.06 [0.04; 0.13] 0.05 [0.03; 0.12] 0.955
IL-4 0.04 [0.03; 0.06] 0.03 [0.02; 0.05] 0.382
IL-6 1.32 [0.97; 1.78] 1.08 [0.71; 1.78] 0.157
IL-10 0.35 [0.25; 0.65] 0.38 [0.22; 0.58] 0.711
FC 515 [379; 1228] 505 [336; 1000] 0.191
All biomarkers are presented as median [interquartile range]. *p-values were calculated according to the Wilcoxon’s signed rank test. Two-sided p-values <0.05 
were considered as statistically significant. Significances [corrected for multiple comparisons] are indicated in bold.
CRP, C-reactive protein; FC, faecal calprotectin; TNF, tumour necrosis factor.
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3.6.3. Metagenomic shotgun sequencing shows that variance 
of microbiome is mainly determined as originating from one 
individual, rather than riboflavin supplementation
To further analyse possible modulating effects on the compos-
ition of the faecal microbiome, we next analysed the microbiome 
in higher resolution by metagenomic shotgun sequencing [MGS]. 
Here, the supplementation of riboflavin did not induce changes in 
the taxonomical diversity within the faecal samples of the patients 
with CD [total patients with CD: p = 0.274; low FC: p = 0.491; 
high FC: p = 0.349, Figure 3]. Also, when calculating the effect of 
riboflavin supplementation on the interindividual variance in the 
microbiome, riboflavin did not significantly affect the variance in 
the taxonomical composition [total CD cohort FDR: = 1.000; low 
FC levels FDR: = 0.910; high FC levels FDR: = 1.000, Figure 4], nor 
in the functional composition [total CD cohort FDR: = 1.000; low 
FC levels FDR: = 1.000; high FC levels FDR: = 1.000, Figure 5]. In 
contrast, when evaluating the effect of paired samples [i.e., samples 
originating from the same CD patient] on the interindividual vari-
ance, it showed that individual sample relatedness does affect the 
variance of the taxonomical composition significantly [total CD co-
hort FDR: = 0.002*; low FC levels FDR: = 0.002*; high FC levels 
FDR: = 0.002*, Figure 4], and of the functional composition [total 
CD cohort FDR: = 0.002*; low FC levels FDR: = 0.002*; high FC 
levels FDR: = 0.002*, Figure 5].
Riboflavin intake also did not induce changes in relative abun-
dances of any species, nor in other taxonomical levels. In the patients 
with CD with low FC levels, the relative abundance of pathway-5189, 
encoding the biosynthesis of tetrapyrrole, was significantly decreased 
after the riboflavin supplementation [FDR = 0.06].
4. Discussion
In this study, subjective and objective CD disease parameters and the 
faecal microbiome were monitored in a cohort of 70 patients with 
CD, with and without elevated faecal calprotectin, during an inter-
vention with oral riboflavin [vitamin B2]. CD disease scores, circu-
lating cytokines, systemic redox status, and the faecal microbiome 
constitution, were compared before and 3 weeks after riboflavin sup-
plementation. Here, we show that riboflavin supplementation has a 
mixed effect on systemic biomarkers of inflammation, with a decrease 
of CRP, ESR, platelets, and IL-2, but in the absence of effects on the 
remaining biomarkers that were measured in this study. Moreover, a 
significant antioxidant effect was observed, as reflected by an increase 
in the concentration of plasma free thiols. In addition, clinical symp-
toms were reduced, as quantified by a reduction in the clinical dis-
ease activity index [HBI] and an improvement in the QoL. However, 
these clinical effects should be interpreted with caution as the pre-
sent study was not placebo-controlled. As determined by FISH, there 
was a small decrease in Enterobacteriaceae in patients with low FC 
levels; however, when the microbiome was characterised by MGS, no 
significant alterations were observed in the faecal microbiota diver-
sity, taxonomy, or metabolic pathway constitution, indicating that 
the observed anti-inflammatory effects of riboflavin supplementation 
might not be mediated through the faecal microbiome. In line, we 
did not observe major differential effects of riboflavin on study out-
come parameters for several important disease phenotypes, such as 
ileocaecal resection status and primary disease localisation.
4.1. Effects of riboflavin on patient-reported 
outcomes
This study showed that clinical symptoms decrease after riboflavin 
supplementation, as quantified by a reduction in the clinical disease 
activity index [HBI] in all CD subgroups, and an improvement in 
the QoL as reflected by the IBD-Q in the total and low FC patient 
groups. However, the current study was not double-blind and placebo-
controlled, which would have helped us to better understand the effects 
of riboflavin supplementation on patient-reported outcomes of disease 
activity [i.e. HBI scores and IBD-Q questionnaire results]. Despite this, 




























Figure 2. [A-B]. Serum levels of CRP and IL-2 significantly decrease within 3 
weeks [T0-T3] of riboflavin supplementation. [A] Serum CRP levels [pg/mL] 
significantly decrease in patients with CD with high FC levels [>200  µg/g]. 
[B] Serum IL-2 levels [pg/mL] significantly decrease in patients with CD with 
low FC levels [<200 µg/g]. *p <0.05 [two-sided]. CRP, C-reactive protein; CD, 
Crohn’s disease; FC, faecal calprotectin.
Table 3. Changes in Harvey-Bradshaw Index [HBI] after 3 weeks of 
riboflavin supplementation.
HBI T0 T3 p-value
Total study population 3 [1; 5] 2 [1; 4] <0.001
FC <200 µg/g 3 [1; 5] 2 [0; 4] <0.001
FC > 00 µg/g 3 [2; 5] 2 [1; 4] 0.007
Response scores are presented as median [interquartile range] with corres-
ponding p-values according to paired Wilcoxon’s signed-rank test. Two-sided 
p-values <0.05 are considered statistically significant. Significances are indi-
cated in bold.
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objective disease parameters, such as several biochemical markers for 
disease activity [i.e., serum cytokines and plasma free thiols].
4.2. Effects of riboflavin on biochemical markers of 
disease activity
4.2.1. Serum cytokine levels
In the total group of patients with CD, we observed a reduction in serum 
concentrations of the pro-inflammatory cytokine IL-2 after 3 weeks of 
riboflavin supplementation. This decrease in serum IL-2 levels was also 
observed in the CD subgroup with low FC levels at baseline. In add-
ition, in the patients with CD with high FC levels at baseline, CRP was 
also shown to be decreased after 3 weeks of riboflavin supplementation. 
In a previous study, it was shown that IL-2 can only be secreted extracel-
lularly after it has undergone oxidative folding [disulphide formation] 
in the endoplasmic reticulum, which is dependent on cellular flavin.29 
Although it is difficult to determine whether the observed alterations 
in cytokine concentrations originated from riboflavin supplementa-
tion, a previous study that profiled circulating cytokines in patients 
with CD, who were under maintenance therapy with infliximab, ob-
served stability in pro-inflammatory cytokine concentrations over a 
course of 6 weeks, possibly indicating that our observed results might 
indeed be induced by the riboflavin supplementation.30 Collectively, this 
Table 4. Changes in quality of life [QoL] of Crohn’s disease [CD] patients as measured by the Inflammatory Bowel Disease Questionnaire 
[IBD-Q] before [T0] and after riboflavin supplementation [T3].
Total study population T0 T3 p-value
Total score IBD-Q 173 [152; 193] 177 [160; 196] 0.001
Bowel symptoms 55 [48; 61] 58 [49; 64] 0.002
Systemic symptoms 22 [19; 27] 24 [19; 29] <0.001
Emotional function 67 [60; 73] 66 [60; 74] 0.257
Social function 32 [26; 35] 32 [26; 34] 0.631
FC <200 µg/g T0 T3 p-value
Total score IBD-Q 175 [157; 200] 178 [162; 205] 0.001
Bowel symptoms 56 [48; 63] 59 [51; 66] 0.005
Systemic symptoms 22 [19; 27] 24 [19; 30] <0.001
Emotional function 68 [61; 73] 67 [61; 82] 0.059
Social function 32 [27; 35] 33 [27; 35] 0.195
FC >200 µg/g T0 T3 p-value
Total score IBD-Q 171 [145; 188] 177 [143; 187] 0.253
Bowel symptoms 53 [47; 60] 57 [48; 61] 0.163
Systemic symptoms 22 [19; 28] 24 [18; 28] 0.127
Emotional function 63 [57; 70] 64 [57; 71] 0.714
Social function 30 [26; 33] 29 [23; 34] 0.361
Response scores are presented as median [interquartile range] with corresponding p-values according to paired Wilcoxon’s signed-rank test. Two-sided p-values 
<0.05 are considered statistically significant. Significances are indicated in bold.
FC, faecal calprotectin.
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Figure 3. [A–C]. Boxplots representing the α-diversities at baseline [T0] and 3 weeks [T3] after intake of riboflavin, between patients with CD. [A] Total CD cohort. 
[B] Low FC group. [C] High FC group [p >0.05]. CD, Crohn’s disease; FC, faecal calprotectin.
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Figure 4. [A–F]. Principal coordinate analyses [PCoAs] of Bray-Curtis distances on species composition, calculated between T0 [before riboflavin] and T3 [3 weeks 
after riboflavin], on [A–B] the total patients, [C–D] the patients with a low baseline FC, and [E–F] patients with a high baseline FC. Each dot represents a patient 
with CD, with the lighter shade representing T0 and the darker shade representing T3. The dashed lines indicates that the faecal samples originate from the same 
CD individual [PCoA1: p >0.05, PCoA2: p >0.05]. CD, Crohn’s disease; FC, faecal calprotectin.
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Figure 5. [A–F]. Principal coordinate analyses [PCoAs] of Bray-Curtis distances on predicted functional composition, calculated between T0 [before riboflavin] 
and T3 [3 weeks after riboflavin], on [A–B] the total patients, [C–D] the patients with a low baseline FC, and [E–F] patients with a high baseline FC. Each dot 
represents a patient with CD, with the lighter shade representing T0 and the darker shade representing T3. The dashed lines indicates that the faecal samples 
originate from the same CD individual [PCoA1: p >0.05, PCoA2: p >0.05]. CD, Crohn’s disease; FC, faecal calprotectin.
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might indicate that the observed effects on the analysed inflammatory 
markers may be ascribed to the anti-inflammatory potential of ribo-
flavin, thereby reducing the inflammatory burden in CD.
4.2.2. Plasma free thiols
In the total group of patients with CD and in the patients with high 
FC at baseline, we observed an increase in plasma free thiols after 
3 weeks of riboflavin supplementation, which is reflective of a re-
duction in systemic oxidative stress. In human metabolism, ribo-
flavin is particularly known for its antioxidant properties, and has 
been documented to reduce ischaemic/reperfusion injury and lipid 
peroxidation, as well as to increase antioxidant enzyme activity, 
such as that of superoxide dismutase [SOD], glutathione peroxidase 
[GPx], and catalase, in animal models.31,32 Also, in the pathogenesis 
of CD, it has been implied that oxidative stress plays an important 
role.33–36 For a long time, plasma free thiols have been proposed as 
a measure of systemic redox status in various inflammatory condi-
tions, but the value of this biomarker in CD has only recently been 
acknowledged.37–39 In CD, it has been demonstrated that plasma free 
thiols are significantly decreased as compared with healthy individ-
uals. Furthermore, there is considerable evidence that flavins lead 
to increased extracellular reducing capacity.40,41 This indicates that 
increasing these levels of thiols, possibly by riboflavin, might alle-
viate oxidative stress and CD-related symptoms.
4.3. Potential mechanism of riboflavin effects—
mediation via the faecal microbiome?
Our primary hypothesis was that riboflavin would increase the 
abundance of F. prausnitzii in the gut of patients with CD. Earlier, 
we showed that riboflavin [vitamin B2] acts as redox mediator in 
the extracellular electron shuttling to oxygen of this bacterium, 
enabling its growth and survival at the aerobic-anaerobic interphase 
of the human gut.40,42,43 Importantly, in a pilot study with healthy 
individuals, an increase in the relative abundance of F. prausnitzii 
was observed after a 2-week period of riboflavin supplementation.11 
However, in the present study, the results from MGS of the faecal 
microbiome led us to reject our hypothesis in patients with CD, 
since after a 3-week period of riboflavin supplementation, no alter-
ations in either the microbiota diversity or in specific taxa, including 
F.  prausnitzii, were observed. Only one gene encoding a single 
pathway involved in the biosynthesis of tetrapyrroles was decreased 
after 3 weeks of riboflavin, in patients with low FC levels at baseline. 
These results are in contrast with the aforementioned pilot study 
and the FISH analysis we performed on the faecal samples. In the 
FISH analysis, no effect on F. prausnitzii abundance was observed, 
though it did lead to a significant decrease in the number of poten-
tially pathogenic Enterobacteriaceae [e.g., Escherichia coli] bacteria 
in the subgroup of patients with CD with low FC levels. We believe 
that the discrepancy in results between FISH and MGS methods 
might have multiple origins. For example, it might be that the cur-
rent study was severely underpowered regarding the metagenomic 
sequencing, provided that study power was sufficient for the FISH 
analysis. Furthermore, we speculate that faecal sample heterogen-
eity may have significantly influenced the differences in results from 
both analytical tools, due to possible interindividual differences in 
sample collection, faecal consistency, sample storage, efficiency of 
DNA extraction, and possible noise in the applied bioinformatics 
tools regarding MGS analysis. Another important aspect regarding 
the FISH probe used for Enterobacteriaceae is its limited target spe-
cificity, since not all members of Enterobacteriaceae are measured.44
4.4. Strengths and limitations
The results of this study are important for several reasons. Currently, 
there are insufficient data to provide evidence-based dietary advice 
to patients with CD.45–49 Previously, only a limited number of studies 
have evaluated the effect of a nutritional intervention [i.e., supple-
mentation of pre- or probiotics] in CD. For example, the effect of the 
prebiotic fructo-oligosaccharides in CD was previously studied in a 
placebo-controlled trial, but in this study no clinical benefit was ob-
served in patients with CD.50 Moreover, the effect of oligofructose-
enriched inulin [OF-IN] was evaluated on patients with CD in an 
double-blind, placebo-controlled study, in which a beneficial modu-
lation of the gut microbiota was demonstrated.51 Similarly, there are 
limited studies evaluating the effect of a vitamin intervention in CD. 
In an interesting randomised controlled study, the effect of a com-
bination of vitamin E and vitamin C was assessed. In this study, a 
significant reducing effect was observed on oxidative stress indices.52 
More recently in a small study, a short vitamin D supplementation 
period resulted in an increase in the abundance of potential benefi-
cial microbiota strains.53 The present prospective study is the first 
clinical study to comprehensively investigate the effect of a ribo-
flavin supplement in a well-described cohort of patients with CD. 
We have assessed the effect of riboflavin on different parameters, 
such as microbiota composition, biomarkers of inflammation and 
oxidative stress, and validated questionnaires of disease severity and 
quality of life.
One of the limitations of this prospective proof-of-concept study 
concerns our definition of CD disease activity. Unfortunately, there 
were no sufficient endoscopic data available for this cohort, which 
are preferentially used as a gold-standard measure of inflammatory 
disease activity. Instead, we used faecal calprotectin levels as an in-
direct, though reliable, surrogate marker for disease activity, and div-
ided our patient cohort into subgroups of either quiescent or active 
disease, based on a faecal calprotectin cut-off level of 200 µg/g. The 
exact cut-off levels of FC presented in the literature are quite arbi-
trary. In our university hospital, a level <60 µg/g is considered indi-
cative of no inflammatory activity, and a level >200 µg/g suggests 
mucosal inflammation. For completeness, we also separated groups 
in a more stringent manner: FC <60 µg/g vs >200 µg/g [high FC], 
and repeated our analysis. However, this did not affect our results 
and main conclusions.
4.5. Conclusions
In conclusion, this prospective clinical study demonstrates that 
riboflavin supplementation of the diet in patients with CD for 3 
weeks results in mixed anti-inflammatory effects and reduced sys-
temic oxidative stress and clinical symptoms [HBI]. Furthermore, 
riboflavin supplementation led to decreased Enterobacteriaceae 
abundance in patients with CD with low FC levels as determined 
by FISH, though MGS analysis did not show evident changes in 
the faecal microbiome. Our data demonstrate that riboflavin sup-
plementation has a number of anti-inflammatory and anti-oxidant 
effects in CD.
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